Utility of Antibiotics in Abscess Management – Systematic Review and Meta-Analysis

Written by Anand Swaminathan REBEL EM Medical Category: Infectious Disease

Background: Skin and soft tissue abscesses are a common emergency department (ED) presentation. The approach to management has changed little in recent decades: incision and drainage (I+D) and then discharge home with follow up. However, increasing rates of methicillin-resistant staph aureus (MRSA) over the last decade have led to further consideration of adjunct therapy with oral antibiotics to improve cure rates. Two recent studies (Talan 2016, Daum 2017) have shown a modest but consistent benefit to oral antibiotics.

Article:

Gottlieb M et al. Systemic Antibiotics for the Treatment of Skin and Soft Tissue Abscesses: A Systematic Review and Meta-Analysis. Ann Emerg Med 2018. [Epub Ahead of Print]

Clinical Question: Do MRSA-active antibiotics improve clinical cure rates amongst patients with abscesses who also receive I+D?

Outcome (Primary): Treatment failures within 21 days

Design: Systematic review and meta-analysis of randomized controlled trials comparing systemic antibiotics with activity against MRSA versus placebo in the treatment of skin and soft tissue abscesses after I+D. The authors searched PubMed, the Cumulative Index of Nursing and Allied Health Literature, Scopus and the Cochrane Database looking for appropriate articles

Excluded: Case reports, case series, retrospective studies, nonrandomized studies and studies published as abstract only

Primary Results:

Search yielded 2,772 references of which, 15 had full-text review

Four studies (with 2,406 patients) included in the systematic review and meta-analysis Three studies performed in the ED only One study performed in ED and outpatient setting

Anti-MRSA antibiotics used: TMP-SMX (3 studies) TMP-SMX or Clindamycin (1 study)

Critical Findings:

Treatment failures (primary outcome) Anti-MRSA antibiotics 7.7% vs Placebo 16.1% Absolute difference: 7.4% ( NNT = 13.5 ) OR = 2.32 (95% CI: 1.75 – 3.08) Statistical Heterogeneity (I 2 ) = 0% Loss to follow up: 6.1%

New lesions at different sites (secondary outcome) Anti-MRSA antibiotics 6.2% vs. Placebo 15.3% Absolute difference: 9.1% ( NNT = 11 ) OR = 0.32 (95% CI: 0.23 – 0.44)

Adverse events Anti-MRSA antibiotics 24.8% vs. Placebo 22.2% NNH = 23



Strengths:

Largest meta-analysis/systematic review to date

PRISMA guidelines used for systematic review and meta-analysis

Multiple databases searched for relevant articles

Two investigators independently extracted data from the studies included in the systematic review

Quality of studies was assessed using the Cochrane Risk of Bias tool

Risk of bias was determined to be low in all studies (a meta-analysis is only as good as the studies that go into it)

Included studies were multicenter increasing external validity

Primary endpoint is patient centered

Statistical heterogeneity was absent for the primary outcome

Limitations:

Results are heavily weighted by two of the four included studies

All studies conducted in US. Unclear if this affects generalizability

Studies did not all use the same antibiotic (Daum et al used clindamycin or TMP-SMX) and did not all use the same dose of antibiotic

Clinical cure (the primary endpoint) was defined differently in the different studies

I+D technique was not standardized in all studies. Inadequate drainage would skew the results

Only one study ( Daum 2017 ) included children < 12 years of age

In the two largest studies ( Talan 2016 Daum 2017 ) patients had significant overlying cellulitis

Compliance with treatment assignment low in Talan article which may reduce adverse event rate

Other Issues:

Though the serious adverse event rate was low, it should be noted widespread use of antibiotics for abscesses (particularly the use of TMP-SMX) may reveal a higher rate of adverse events

Authors Conclusions: “The use of systemic antibiotics for skin and soft tissue abscesses after incision and drainage resulted in an increased rate of clinical cure. Providers should consider the use of antibiotics while balancing the risk of adverse events.”

Our Conclusions: We agree with the authors. The available evidence demonstrates a modest but consistent benefit to adjunct, anti-MRSA antibiotics after I+D of simple abscesses in terms of clinical cure and occurrence of new lesions without a significant increase in adverse events.

However, four issues deserve to be stressed:

Many of the patients included in the recent studies by Talan and Daum had significant overlying cellulitis. This clouds the issue of whether we are treating the abscess or the cellulitis with the antibiotics. Expanded use of anti-MRSA antibiotics will increase the rate of serious adverse events (C. diff diarrhea, hyperkalemia, Steven’s Johnson Syndrome, hypersensitivity reactions etc) in comparison to standard care with no antibiotics The clinical cure rate without antibiotics is high: 84%. Most patients will improve without antibiotics and, thus, delayed use or addition at follow up may be a superior strategy Widespread antibiotic use will likely change the resistance patterns of staphylococcus aureus

Potential to Impact Current Practice: The findings of this systematic review and meta-analysis show strong evidence that antibiotic therapy, in addition to I&D, leads to higher cure rates for small abscesses with overlying cellulitis. These findings should not be taken to mean that all patients with abscesses who are I&D’d in the ED will need antibiotics as the majority of abscesses (84%) will resolve with I&D alone. The increased clinical cure rate must be weighed against the potential risks associated with increase antibiotic use such as adverse medication-related events and increasing antibiotic resistance.

Bottom Line: ED providers should consider adjunctive therapy with oral antibiotics with MRSA coverage after I&D of simple, small (<5cm) abscesses with overlying cellulitis in healthy individuals to increase short-term cure rates. The presence of significant overlying cellulitis continues to warrant adjunctive therapy with antibiotics.

Read More:

References:

Talan DA et al. Trimethoprim–Sulfamethoxazole versus placebo for uncomplicated skin abscess. NEJM 2016; 374(9): 823-32. PMID: 26962903 Daum RS et al. A placebo-controlled trial of antibiotics for smaller skin abscesses. NEJM 2017; 376(26): 2545-55. PMID: 28657870 Schmitz GR et al. Randomized Controlled Trial of Trimethoprim-Sulfamethoxazole for Uncomplicated Skin Abscesses in Patients at Risk for Community-Associated Methicillin-Resistant Staphylococcus aureus Infection. Ann Emerg Med 2010; 56(3): 283-7. PMID: 20346539

Post Peer Reviewed By: Salim R. Rezaie (Twitter: @srrezaie)